AGTC 0106

Drug Profile

AGTC 0106

Alternative Names: AGTC-0106; Alpha-1 antitrypsin deficiency gene therapy - Applied Genetic Technologies Corporation; rAAV1-CB-hAAT; Recombinant AAV-AAT vector gene therapy - AGTC

Latest Information Update: 22 Aug 2016

Price : $50

At a glance

  • Originator Applied Genetic Technologies Corporation
  • Developer Applied Genetic Technologies Corporation; National Heart, Lung and Blood Institute
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alpha 1-antitrypsin deficiency

Most Recent Events

  • 05 May 2016 Pharmacodynamics data from a phase I trial in Alpha-1-antitrypsin deficiency released by Applied Genetic Technologies Corporation
  • 20 Jan 2016 Pharmacodynamics data from a phase II trial in Alpha-1-antitrypsin deficiency released by Applied Genetic Technologies Corporation
  • 01 Oct 2015 Applied Genetic Technologies Corporation completes its phase II trial for Alpha 1-antitrypsin deficiency in USA & Ireland (NCT01054339)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top